Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the counter (OTC) and biosimilar products for patients around the world. With commercial footprint in over 35 markets, Alvogen’s key regions include the U.S. and emerging markets in the CEE and APAC regions.
Alvogen's product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology, in addition to a fast-growing portfolio of biosimilars, brands and OTC products.
Our true purpose as a company is to make people's lives better by producing high quality medicines that help people live longer, healthier and more active lives and making them more accessible to those who might not otherwise be able to afford them.
Over 40 managers from Alvogen and Alvotech will be attending CPhI Worldwide 2019 from 5 - 7 November this year. CPhI is the top event of the year in the pharma industry calendar and one of the largest networking events in the world. This year over 45,000 visitors from 150 countries are expected at the trade fair.
This year CPhI will be celebrating its 30th anniversary and we look forward to meeting you there!